Back to Journals » Cancer Management and Research » Volume 10

A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma

Authors Yu Y, Feng X, Cang S

Received 2 December 2017

Accepted for publication 17 March 2018

Published 13 June 2018 Volume 2018:10 Pages 1507—1515

DOI https://doi.org/10.2147/CMAR.S158712

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Nakshatri


Yang Yu,* Xiao Feng,* Shundong Cang

Department of Oncology, Henan Province People’s Hospital, Henan University, Zhengzhou, Henan, China

*These authors contributed equally to this work

Background and aim: Some cancer-specific miRNAs are dysregulated in pancreatic adenocarcinoma (PAAD) and involved in cell autophagy, differentiation, proliferation, migration, invasion, and malignant transformation. The aim of our study was to determine a panel of new diagnostic and prognostic biomarkers for PAAD.
Methods: We conducted a comprehensive analysis of global miRNA-expression profiles and corresponding prognosis information of 168 PAAD patients from the Cancer Genome Atlas data set. A total of 16 differentially expressed miRNAs were identified as aberrantly expressed in PAAD, and six of these were evaluated for use as diagnostic markers for PAAD. Next, we confirmed a two-miRNA signature significantly associated with PAAD patient diagnosis and outcome prediction.
Results: The panel of two miRNAs showed outstanding diagnostic performance, with sensitivity of 100% and specificity of 87.5%. Finally, we divided the PAAD patients into high-risk and low-risk groups based on the expression profile of the two miRNAs. Kaplan–Meier analysis demonstrated that patients in the high-risk group had significantly worse prognosis than patients in the low-risk group. Univariate and multivariate Cox regression analysis showed that the two-miRNA signature was an independent prognostic factor for the overall survival of PAAD patients.
Conclusion: Taken together, the two-miRNA signature may serve as an accurate and sensitive biomarker for diagnosis and PAAD-outcome prediction, facilitating the diagnosis and potentially improving treatment outcome of PAAD.

Keywords: pancreatic adenocarcinoma, microRNA signature, TCGA, prognosis, diagnosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]